Internationalization

INTERNATIONALIZATION

Internationally Advanced R&D Technology

CSPC Innovation has established a globally leading biosimilar drug R&D platform, launched China's first mRNA vaccine, and is leading China's mRNA technology to match international advanced standards.

Cutting-edge National Business Cooperation

CSPC Innovation Pharmaceutical Co., Ltd. and Its Related Parties Enter into Strategic Cooperation and Licence Agreement with AstraZeneca

On January 30, 2026, CSPC Innovation Pharmaceutical Co., Ltd., its holding subsidiary CSPC Megalith Biopharmaceutical Co., Ltd. together with its related parties CSPC Group Co., Ltd. and CSPC Zhongqi Pharmaceutical Technology(shijiazhuang) CO.,LTD. entered into a Strategic Cooperation and Licence Agreement with AstraZeneca on January 29, 2026. The parties will conduct comprehensive strategic cooperation in the discovery of innovative peptide molecules and the development of long‑acting

CSPC Megalith Biopharmaceutical Co., Ltd.Signs Cooperation, Option and Licence Agreement with AstraZeneca

On July 1, 2026, CSPC Innovation Pharmaceutical Co., Ltd.’s holding subsidiary CSPC Megalith Biopharmaceutical Co., Ltd. entered into a Cooperation, Option and Licence Agreement with AstraZeneca. The two parties will carry out strategic cooperation in the field of novel small‑interfering nucleic acid candidate drugs to develop novel extrahepatic‑delivered small‑interfering nucleic acid candidate molecules.